Have you seen our latest Drugs to Watch Report? We take a closer look at the pipeline and a new drug in development that may provide a therapeutic alternative and increased tolerability for people with schizophrenia. Read the full Q3 2024 report here: https://cvs.co/3VTzo75
CVS Caremark’s Post
More Relevant Posts
-
Don't let regulatory hurdles stop your depression drug from reaching the market. Join our webinar tomorrow to learn how to navigate US and EU regulations and clinical trial requirements effectively: https://bit.ly/4ab1q2g #MDD #Depression #webinar
-
On December 12, 2023, the Multidisciplinary Association for Psychedelic Studies Public Benefit Corporation (“MAPS PBC”) announced that it has submitted a new drug application (“NDA”) to the FDA for the use of 3,4-Methylenedioxymethamphetamine (“MDMA”) for the treatment of post-traumatic stress disorder (“PTSD”). To read the full article, visit https://lnkd.in/eRRs59FZ. #obermanlaw #advisoryinsights #emergingmarkets
-
-
Regulatory Specialist ► We provide high-quality regulatory affairs consulting that is tailored to Sponsors' individual needs, and designed to get therapeutics to market as quickly as possible.
A novel drug becomes an approved treatment for patients with Friedreich ataxia (FA), according to a study recently published in Expert Review of Neurotherapeutics. Omaveloxolone emerges as a representation of progress, offering a substantial leap in FA treatment with the potential to benefit most of the affected population. The data underlining the drug’s efficacy is consistent and reveals a reassuringly low incidence of adverse events across multiple studies. More in the article linked below in the comments. #rarediseases #fdaapproved #researchanddevelopment
-
🎉 Excited to share that my latest research paper, titled "Risk and Protective Factors Affecting Drug Craving among Patients with Substance Use Disorders Undergoing Opioids Agonists Maintenance Therapy" has been published! 📚🔬 This work has been a culmination of dedication, collaboration, and countless hours of research. You can find the full paper below. #Research #Publication #AcademicAchievement
Risk and Protective Factors Affecting Drug Craving among Patients with Substance Use Disorders Undergoing Opioids Agonists Maintenance Therapy
tandfonline.com
-
Playing with Psychedelics Remains Dangerous on Many Levels – Especially if there is an ‘Interrupter’ Med! #preventdontpromote #drug use Trip-killers: a concerning practice associated with psychedelic drug use. Psychedelic drugs such as lysergic acid diethylamide (LSD) and psilocybin (‘magic mushrooms’) induce hallucinations and distort thought-processes. The intensity of a psychedelic ‘trip’ can cause distress, agitation, and even psychosis. A recent report showed that at least 8.4% of drug-related presentations to European emergency departments involve psychedelics. This proportion may increase as the clinical use of these agents expands. For more https://lnkd.in/gDGYppzc
-
-
Founder & CEO, Universal Brain | MD | Building Better Outcomes for Psychiatric Patients Through Precise EEG Analytic Technology
This new study from Nature, authored by George I Papakostas et al, was able to show the superiority of rTMS over drug augmentation or drug change for TRD. I believe these are great findings! According to this study, rTMS augmentation is a more effective treatment option for treatment-resistant depression than switching antidepressants. I think clinicians should consider rTMS augmentation as an early intervention for patients with treatment-resistant depression. When it comes to treatment-resistant depression, there's a big evidence gap "with respect to whether pharmacological or non-pharmacological augmentation is superior to antidepressant switch, or vice-versa". Full article title: https://lnkd.in/gk-gunwh "Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial" #TRD #MentalHealth #Depression
-
-
Discover AWKN-P001, Awakn's novel #psychedelic Medication-Assisted Therapy (MAT) of an N-methyl-D-aspartate receptor-modulating drug (#ketamine) used in combination with psycho-social support to treat Severe #AlcoholUseDisorder. https://bit.ly/47JaPO3
Research & Development - Awakn Life Sciences
https://awaknlifesciences.com
-
What exactly is 'treatment-resistant depression' (TRD)? How are 'inadequate response' and 'partial response' defined? Here, Dr. Andrew Cutler and Dr. Roger McIntyre discuss these questions and more! Presented at the 2023 NEI Congress, session titled, "You Can Hurry Drugs: Rapid-Acting Antidepressants, Treatment Resistance, and Neuroplasticity". You can watch the lecture by creating a free NEI guest account here: https://lnkd.in/eabenHtt
Product Leader advancing product management excellence + agility at scale
2wWhy doesn’t CVS Caremark align their clinical policies with the FDA approvals for breakthrough/priority medications? It’s wonderful that these are getting FDA approved, but your members can’t actually obtain coverage for them. I reviewed the Xolair clinical policies for food allergies with all major carriers (twelve in total), and CVS Caremark is the ONLY one that doesn’t align with the FDA. It’s FDA approved for patients with one or more IgE mediated food allergies, yet you require someone to have peanut AND TWO OTHER food allergies. This potentially life saving medication is now inaccessible for so many of your members, including my child. Why?